Janssen’s subcutaneous amivantamab gains CHMP backing for EGFR-mutated lung cancer
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the extension of marketing ... Read More
Johnson & Johnson’s RYBREVANT and LAZCLUZE show unprecedented survival advantage in lung cancer trial
Johnson & Johnson has revealed transformative results from the Phase 3 MARIPOSA clinical trial, positioning the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) as a ... Read More
Johnson & Johnson’s RYBREVANT approved by FDA as second-line option for EGFR-mutated NSCL
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's RYBREVANT (amivantamab-vmjw) in combination with chemotherapy for the treatment of adult patients with ... Read More
FDA approves RYBREVANT and LAZCLUZE for EGFR-mutated advanced lung cancer
The U.S. Food and Drug Administration (FDA) has approved the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) as a first-line therapy for adults with advanced ... Read More